Our Research

Dr. Mohapatra trained as a molecular biologist, immunologist and a gene therapist became fascinated by the power of nanoscale advantages in 2002, as the national nano initiative was taking shape. Inspired by the molecular and nanoscale events occurring naturally within a cell, his research group designed and developed new nanobiotechnology methods, devices and tools based on genetically engineered proteins and cells that can be employed in point-of-care diagnostic and therapeutic applications. 

Specifically, his team employs an array of nano-bio-engineering and biochemical methods to develop nanoscale biosensors, and molecular diagnostic tools (such as the HIV test in 20 Sec) for use in resource-limited and field conditions. Additionally, his team is focused on the creation of targeted and responsive nanocarrier-based imaging and drug delivery systems capable of delivering the right dose of drug at the right location in the body and at the right time, which present numerous advantages over current state-of-the-art approaches.

His current research focuses on discovering and developing a) kidney glomeruli-targeted drug delivery systems for glomerulo nephritis (RO1-funded)), b) brain-targeted drug/gene/RNA delivery systems against traumatic brain injury (VA-funded) and Alzheimer’s disease (RO1-funded) and c) a lung-targeted drug/gene/RNA delivery systems for viral respiratory infections (VA-funded). It is expected that Dr. Mohapatra’s highly innovative applications of diverse nanomedicine approaches have already made impact and are expected to lead to high-impact clinical diagnostics and therapies for Veterans and other Americans in need.

Learn more about our research